Royalty Pharma PLC RPRX

US Pharmaceuticals

$58.21 ▼ -0.14% ($-0.08)

Open $58.50

Prev Close $58.29

Day Range $57.68 – $58.50

52W Range $34.63 – $64.38

Market Cap $33.47B

P/E (TTM) 41.07

Beta 0.39

Div Yield 2.96%

EPS (TTM) $1.46

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-06-16
Shares Out.	575,830,000
Website	royaltypharma.com/ ↗
Phone	12128830200
Employees	100
Revenue	$674.1M
Gross Profit	$674.1M
Net Income	$81.5M
Free Cash Flow	$2.98B
Total Assets	$19.82B
Total Liabilities	$10.03B
Equity	$9.79B

About Royalty Pharma PLC

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC is a publicly traded company under the ticker symbol RPRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.